Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab in active rheumatoid arthritis despite DMARD therapy
2010-022242-24Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Sirukumab with Placebo (2 arms). Primary endpoints: ACR20 response and Radiographic progression. Started May 2012; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022242-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022242-24.